H.B. Fuller’s Earnings Miss Estimates, FY24 Outlook Lowered

H.B. Fuller Company (FUL) saw its shares drop in premarket trading after the company reported disappointing third-quarter results and lowered its full-year guidance. Revenue missed expectations, while organic revenue growth was muted due to pricing adjustments. Despite gross profit and EBITDA improvements, adjusted EPS fell short of forecasts, prompting a reduction in the company’s FY24 outlook.

Energy Transfer’s Upcoming Earnings Report: What Investors Need to Know

Energy Transfer is set to release its quarterly earnings on August 7th, 2024. Analysts anticipate an earnings per share (EPS) of $0.36, but investors will be keen to see if the company surpasses estimates and provides positive guidance for the next quarter. This analysis delves into Energy Transfer’s past performance, analyst sentiment, and key financial metrics to help investors understand what to expect.

IBM Surpasses Q1 Earnings Estimates

IBM has released its financial results for the first quarter of 2024, exceeding analysts’ expectations. The company reported earnings per share (EPS) of $1.68, surpassing the estimated $1.60 EPS. However, revenue came in slightly below estimates, with reported revenue of $14.46 billion compared to the anticipated $14.55 billion.

Ford Motor Q1 Earnings Beat Estimates

Ford Motor reported earnings per share (EPS) of $0.49 for the first quarter, exceeding analyst estimates of $0.42. Revenue for the quarter came in at $42.8 billion, slightly below the consensus estimate of $42.94 billion. Ford’s stock price closed at $13.04, up from $11.39 three months ago and $11.78 one year ago. Over the last 90 days, the company has received four positive EPS revisions and three negative revisions.

Biomarin Pharma Surpasses Analysts’ Expectations in Q1, Raises Guidance

Biomarin Pharma (NASDAQ: BMRN) exceeded analysts’ estimates in its first-quarter results. The company reported an EPS of $0.71, $0.39 higher than the consensus estimate of $0.32. Revenue for the quarter came in at $649 million, in line with the estimate of $649.27 million. Biomarin Pharma also raised its guidance for fiscal year 2024, with EPS expected to be between $2.75 and $2.95 and revenue projected to range from $2.70 billion to $2.80 billion.

Biogen Reports Mixed Q1 Results, Exceeding EPS Expectations but Missing Revenue Estimates

Biogen’s first quarter 2024 earnings report revealed an adjusted EPS of $3.67, surpassing the consensus estimate of $3.43. Revenue, however, slightly missed expectations at $2.29 billion against the consensus estimate of $2.31 billion, reflecting a 7% decline compared to the same quarter last year. Despite the revenue shortfall, the company experienced a 10% increase in GAAP operating income and a 24% increase in adjusted operating income, driven by efficiency gains from its Fit for Growth program and research and development prioritization. The introduction of LEQEMBI, a new Alzheimer’s treatment, showed promise with global in-market sales of $19 million in the first quarter, nearly tripling since the fourth quarter of 2023. Biogen maintained its full-year 2024 financial guidance, projecting an adjusted EPS range of $15.00 to $16.00, representing approximately 5% growth at the mid-point compared to 2023. The company anticipates a low- to mid-single digit percentage decline in total revenue but expects operating income to grow by a low-double digit percentage.

Scroll to Top